Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
48
CNTA Quote, Financials, Valuation and Earnings
Last price:
$25.35
Seasonality move
:
6.31%
Day range:
$25.07 - $25.97
52-week range:
$9.60 - $30.58
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
224.12x
P/B ratio:
12.42x
Volume:
465.5K
Avg. volume:
1.6M
1-year change:
46.76%
Market cap:
$3.7B
Revenue:
--
EPS (TTM):
-$1.82
Analysts' Opinion
-
Consensus RatingCentessa Pharmaceuticals Plc has received a consensus rating of Buy. The company's average rating is a Buy based on 11 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $37.67, Centessa Pharmaceuticals Plc has an estimated upside of 53.06% from its current price of $25.33.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $30.00 representing 100% downside risk from its current price of $25.33.
Fair Value
-
According to the consensus of 11 analysts, Centessa Pharmaceuticals Plc has 53.06% upside to fair value with a price target of $37.67 per share.
CNTA vs. S&P 500
-
Over the past 5 trading days, Centessa Pharmaceuticals Plc has overperformed the S&P 500 by 0.53% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Centessa Pharmaceuticals Plc does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Centessa Pharmaceuticals Plc has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Centessa Pharmaceuticals Plc reported revenues of --.
Earnings Growth
-
Centessa Pharmaceuticals Plc earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Centessa Pharmaceuticals Plc reported earnings per share of -$0.41.
Enterprise value:
3.6B
EV / Invested capital:
--
Price / LTM sales:
224.12x
EV / EBIT:
--
EV / Revenue:
240.17x
PEG ratio (5yr expected):
-0.74x
EV / Free cash flow:
-19.95x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$14.1M
Return On Assets:
-45.54%
Net Income Margin (TTM):
-1607.38%
Return On Equity:
-62.59%
Return On Invested Capital:
-48.61%
Operating Margin:
-205.18%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | $6.9M | $15.1M | -- | -- | |
| Gross Profit | -$600.5K | $5.9M | $14.1M | -$238.4K | -$235.6K | |
| Operating Income | -$178.4M | -$162.5M | -$213.6M | -$46.9M | -$53.5M | |
| EBITDA | -$177.8M | -$161.5M | -$212.6M | -$46.6M | -$53.2M | |
| Diluted EPS | -$1.66 | -$1.53 | -$1.82 | -$0.37 | -$0.41 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $611.6M | $477M | $332.5M | $568.4M | $307.7M | |
| Total Assets | $612.2M | $479.4M | $377.4M | $609.7M | $448.3M | |
| Current Liabilities | $29.1M | $38.2M | $35M | $26.4M | $29.1M | |
| Total Liabilities | $63.1M | $106.4M | $118M | $110.6M | $146.7M | |
| Total Equity | $549.1M | $372.9M | $259.4M | $499.1M | $301.6M | |
| Total Debt | -- | $68.2M | $83M | $84.1M | $117.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$182.6M | -$130.8M | -$180.9M | -$21.8M | -$58.1M | |
| Cash From Investing | -$109.7M | -$12M | -$176.1M | $45M | $63.5M | |
| Cash From Financing | $14.7M | $369.8M | $9.6M | $247.6M | $3.4M | |
| Free Cash Flow | -$183.4M | -$130.9M | -$181.3M | -$21.8M | -$58.4M | |
CNTA
Sector
Market Cap
$3.7B
$28.2M
Price % of 52-Week High
82.83%
51.2%
Dividend Yield
0%
0%
Shareholder Yield
-0.72%
-1.54%
1-Year Price Total Return
46.76%
-18.1%
Beta (5-Year)
--
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$25.26
200-day SMA
Buy
Level
$18.38
Bollinger Bands (100)
Buy
Level
19.06 - 26.98
Chaikin Money Flow
Buy
Level
12.1M
20-day SMA
Sell
Level
$27.21
Relative Strength Index (RSI14)
Sell
Level
42.47
ADX Line
Sell
Level
23.07
Williams %R
Buy
Level
-81.9033
50-day SMA
Sell
Level
$25.93
MACD (12, 26)
Sell
Level
-0.40
25-day Aroon Oscillator
Sell
Level
-36
On Balance Volume
Neutral
Level
5.5M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (4.9471)
Sell
CA Score
(Annual)
Level (-1.5787)
Buy
Beneish M-Score
(Annual)
Level (-5.5679)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (1.9358)
Sell
Piotroski F Score
(Annual)
Level (3)
Sell
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Centessa Pharmaceuticals Plc operates as clinical-stage pharmaceutical company, which engages in discovering and developing medicines that delivers transformational to patients. Its portfolio include preclinical to phase three uncorrelated programs spanning diseases with high unmet need across oncology, hematology, immunology, inflammation, neuroscience, and rare diseases. The company was founded on October 26, 2020 and is headquartered in Altrincham, the United Kingdom.
Stock Forecast FAQ
In the current month, CNTA has received 11 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CNTA average analyst price target in the past 3 months is $37.67.
-
Where Will Centessa Pharmaceuticals Plc Stock Be In 1 Year?
According to analysts, the consensus estimate is that Centessa Pharmaceuticals Plc share price will rise to $37.67 per share over the next 12 months.
-
What Do Analysts Say About Centessa Pharmaceuticals Plc?
Analysts are divided on their view about Centessa Pharmaceuticals Plc share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Centessa Pharmaceuticals Plc is a Sell and believe this share price will drop from its current level to $30.00.
-
What Is Centessa Pharmaceuticals Plc's Price Target?
The price target for Centessa Pharmaceuticals Plc over the next 1-year time period is forecast to be $37.67 according to 11 Wall Street analysts, 11 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CNTA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Centessa Pharmaceuticals Plc is a Buy. 11 of 11 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CNTA?
You can purchase shares of Centessa Pharmaceuticals Plc via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Centessa Pharmaceuticals Plc shares.
-
What Is The Centessa Pharmaceuticals Plc Share Price Today?
Centessa Pharmaceuticals Plc was last trading at $25.35 per share. This represents the most recent stock quote for Centessa Pharmaceuticals Plc. Yesterday, Centessa Pharmaceuticals Plc closed at $25.33 per share.
-
How To Buy Centessa Pharmaceuticals Plc Stock Online?
In order to purchase Centessa Pharmaceuticals Plc stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get CNTA Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CNTA
Sector
P/E ratio
--
23.92x
PEG ratio
-0.74x
-0.01x
P/B ratio
12.42x
1.83x
Price / LTM sales
224.12x
1.61x
Growth Metrics
CNTA
Sector
Revenue growth
--
4.6%
Earnings growth
-9.95%
10.88%
Revenue (5-year growth)
--
6.46%
Earnings forecast
-$0.41
-$0.21
Profitability
CNTA
Sector
Profitability FY 2024
-$942.4K
$3.5M
Return on invested capital
-48.61%
-31.84%
Return on assets
-45.54%
-27.96%
Return on equity
-62.59%
-37.63%
Earnings Date
Last Earnings Date
Nov
5
Next Earnings Date
Mar
24
Estimated Next Earnings Date
Feb
4
Balance Sheet
CNTA
Sector
Total cash
$246.2M
$26.3M
Short term investments
$99M
$25.7M
Total assets
$579.5M
$76.9M
Long term debt
$117.6M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
